Insider Trading activities of Amicus Therapeutics Inc insiders. , Part 2

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Amicus Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Amicus Therapeutics Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Amicus Therapeutics Inc since 2005. The reporting company's ticker symbol is FOLD. The reporting company's CIK number is 1178879.
The total value of stock buying since 2005 is $164,250,780.
The total value of stock sales since 2005 is $231,109,482.
The total value of stock option exercises since 2005 is $25,208,054.


 1   2   3 

Table 2. Detailed insider stock purchases, sales, and option exercises of Amicus Therapeutics Inc insiders (FOLD) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2015-07-01 Peist Kenneth (VP, Legal & IP) Sale 10,000 13.98 139,770
2015-07-01 Peist Kenneth (VP, Legal & IP) Option Ex 10,000 13.98 139,770
2015-06-23 Hayden Donald J Jr (Director) Sale 55,000 14.01 770,385
2015-06-23 Hayden Donald J Jr (Director) Option Ex 55,000 14.01 770,385
2015-06-22 Castelli Jeff (SVP, Program Management) Sale 18,981 13.94 264,633
2015-06-22 Castelli Jeff (SVP, Program Management) Option Ex 18,981 13.94 264,633
2015-06-22 Valenzano Ken (SVP, Pharmacology & Biology) Sale 20,500 13.85 284,007
2015-06-22 Valenzano Ken (SVP, Pharmacology & Biology) Option Ex 20,500 13.85 284,007
2015-06-19 Baird William D Iii (Chief Financial Officer) Sale 15,235 13.26 202,061
2015-06-19 Baird William D Iii (Chief Financial Officer) Option Ex 15,235 13.26 202,061
2015-06-19 Dilone Enrique (SVP, Technical Operations) Sale 14,045 13.26 186,278
2015-06-19 Dilone Enrique (SVP, Technical Operations) Option Ex 14,045 13.26 186,278
2015-06-19 Campbell Bradley L (Chief Operating Officer) Sale 13,000 13.26 172,419
2015-06-19 Campbell Bradley L (Chief Operating Officer) Option Ex 13,000 13.26 172,419
2015-06-15 Yu Julie (VP Clinical Ops & Data Mgmt) Sale 8,195 14.17 116,123
2015-06-15 Castelli Jeff (SVP, Program Management) Sale 7,377 14.17 104,532
2015-06-08 Castelli Jeff (SVP, Program Management) Sale 17,312 12.87 222,805
2015-06-08 Castelli Jeff (SVP, Program Management) Option Ex 17,312 12.87 222,805
2015-06-08 Crowley John F (Chairman & CEO) Sale 55,000 13.01 715,550
2015-06-08 Crowley John F (Chairman & CEO) Option Ex 55,000 13.01 715,550
2015-05-11 Yu Julie (VP Clinical Ops & Data Mgmt) Sale 7,500 10.85 81,337
2015-05-11 Castelli Jeff (SVP, Program Management) Sale 10,000 10.84 108,370
2015-05-11 Gershkowitz Jayne (SVP, Chief Patient Advocate) Sale 10,000 10.84 108,390
2015-05-11 Baird William D Iii (Chief Financial Officer) Sale 24,800 10.84 268,807
2015-05-11 Quimi Daphne (VP Finance and Controller) Sale 7,500 10.84 81,307
2015-05-11 Dilone Enrique (SVP, Technical Operations) Sale 10,000 10.85 108,450
2015-05-11 Peist Kenneth (VP, Legal & IP) Sale 12,500 10.84 135,487
2015-05-11 Valenzano Ken (SVP, Pharmacology & Biology) Sale 13,000 10.85 140,998
2015-05-11 Kirk John (VP, Regulatory Affairs) Sale 10,000 10.84 108,360
2015-05-11 Campbell Bradley L (Chief Operating Officer) Sale 24,800 10.84 268,807
2015-05-08 Barth Jay (Chief Medical Officer) Option Ex 25,000 .00 0
2015-05-08 Yu Julie (VP Clinical Ops & Data Mgmt) Option Ex 25,000 .00 0
2015-05-08 Castelli Jeff (SVP, Program Management) Option Ex 25,000 .00 0
2015-05-08 Gershkowitz Jayne (SVP, Chief Patient Advocate) Option Ex 25,000 .00 0
2015-05-08 Baird William D Iii (Chief Financial Officer) Option Ex 50,000 .00 0
2015-05-08 Quimi Daphne (VP Finance and Controller) Option Ex 25,000 .00 0
2015-05-08 Dilone Enrique (SVP, Technical Operations) Option Ex 25,000 .00 0
2015-05-08 Peist Kenneth (VP, Legal & IP) Option Ex 25,000 .00 0
2015-05-08 Valenzano Ken (SVP, Pharmacology & Biology) Option Ex 25,000 .00 0
2015-05-08 Kirk John (VP, Regulatory Affairs) Option Ex 25,000 .00 0
2015-05-08 Campbell Bradley L (Chief Operating Officer) Option Ex 50,000 .00 0
2015-04-15 Valenzano Ken (VP, Pharmacology & Biology) Sale 5,000 12.50 62,500
2015-04-15 Valenzano Ken (VP, Pharmacology & Biology) Option Ex 5,000 12.50 62,500
2015-04-15 Sblendorio Glenn (Director) Sale 20,000 12.50 250,000
2015-04-15 Sblendorio Glenn (Director) Option Ex 20,000 12.50 250,000
2015-04-10 Crowley John F (Chairman & CEO) Sale 11,678 12.00 140,136
2015-04-10 Crowley John F (Chairman & CEO) Option Ex 11,678 12.00 140,136
2015-04-01 Castelli Jeff (VP, Program Management) Sale 9,489 10.70 101,484
2015-04-01 Castelli Jeff (VP, Program Management) Option Ex 9,489 10.70 101,484
2015-03-20 Yu Julie (VP Clinical Ops & Data Mgmt) Sale 7,785 11.51 89,581
2015-03-20 Yu Julie (VP Clinical Ops & Data Mgmt) Option Ex 7,785 11.51 89,581
2015-03-20 Gershkowitz Jayne (VP, Patient Advocacy) Sale 10,648 11.51 122,569
2015-03-20 Gershkowitz Jayne (VP, Patient Advocacy) Option Ex 10,648 11.51 122,569
2015-03-20 Baird William D Iii (Chief Financial Officer) Sale 15,235 11.51 175,293
2015-03-20 Baird William D Iii (Chief Financial Officer) Option Ex 15,235 11.51 175,293
2015-03-20 Dilone Enrique (VP, Technical Operations) Sale 14,045 11.51 161,671
2015-03-20 Dilone Enrique (VP, Technical Operations) Option Ex 14,045 11.51 161,671
2015-03-20 Peist Kenneth (VP, Legal & IP) Sale 10,000 11.52 115,160
2015-03-20 Peist Kenneth (VP, Legal & IP) Option Ex 10,000 11.52 115,160
2015-03-20 Valenzano Ken (VP, Pharmacology & Biology) Sale 20,801 11.71 242,687
2015-03-20 Valenzano Ken (VP, Pharmacology & Biology) Option Ex 19,093 11.60 221,063
2015-03-20 Kirk John (VP, Regulatory Affairs) Sale 10,110 11.51 116,355
2015-03-20 Kirk John (VP, Regulatory Affairs) Option Ex 10,110 11.51 116,355
2015-03-20 Crowley John F (Chairman & CEO) Sale 268,322 11.49 3,082,214
2015-03-20 Crowley John F (Chairman & CEO) Option Ex 268,322 11.49 3,082,214
2015-03-20 Campbell Bradley L (Chief Operating Officer) Sale 12,999 11.51 149,592
2015-03-20 Campbell Bradley L (Chief Operating Officer) Option Ex 12,999 11.51 149,592
2015-01-05 Castelli Jeff (VP, Program Management) Sale 4,667 9.00 42,003
2015-01-05 Castelli Jeff (VP, Program Management) Option Ex 4,667 9.00 42,003
2014-12-04 Crowley John F (Chairman & CEO) Buy 89,000 8.36 743,951
2014-12-04 Crowley John F (Chairman & CEO) Sale 89,000 8.36 743,951
2014-11-25 Castelli Jeff (VP, Program Management) Buy 8,103 8.00 64,824
2014-11-25 Castelli Jeff (VP, Program Management) Sale 8,103 8.00 64,824
2014-11-25 Baird William D Iii (Chief Financial Officer) Buy 10,000 8.00 80,000
2014-11-25 Baird William D Iii (Chief Financial Officer) Sale 10,000 8.00 80,000
2014-11-25 Quimi Daphne (VP Finance and Controller) Buy 3,500 8.00 28,000
2014-11-25 Quimi Daphne (VP Finance and Controller) Sale 3,500 8.00 28,000
2014-11-25 Dilone Enrique (VP, Technical Operations) Buy 7,000 8.00 56,000
2014-11-25 Dilone Enrique (VP, Technical Operations) Sale 7,000 8.00 56,000
2014-11-25 Peist Kenneth (VP, Legal & IP) Buy 4,500 8.00 36,000
2014-11-25 Peist Kenneth (VP, Legal & IP) Sale 4,500 8.00 36,000
2014-11-25 Valenzano Ken (VP, Pharmacology & Biology) Buy 25,000 8.00 200,000
2014-11-25 Valenzano Ken (VP, Pharmacology & Biology) Sale 25,000 8.00 200,000
2014-11-25 Campbell Bradley L (Chief Operating Officer) Buy 7,250 8.00 58,000
2014-11-25 Campbell Bradley L (Chief Operating Officer) Sale 7,250 8.00 58,000
2014-11-19 Perceptive Life Sciences Master Fund Ltd Buy 2,100,000 6.50 13,650,000
2014-10-27 Glaxosmithkline Plc Sale 11,315,825 5.29 59,872,030
2014-10-03 Yu Julie (VP Clinical Ops & Data Mgmt) Buy 3,200 7.00 22,400
2014-10-03 Yu Julie (VP Clinical Ops & Data Mgmt) Sale 3,200 7.00 22,400
2014-10-03 Castelli Jeff (VP, Program Management) Buy 8,552 7.00 59,864
2014-10-03 Castelli Jeff (VP, Program Management) Sale 8,552 7.00 59,864
2014-10-03 Baird William D Iii (Chief Financial Officer) Buy 10,000 7.00 70,000
2014-10-03 Baird William D Iii (Chief Financial Officer) Sale 10,000 7.00 70,000
2014-10-03 Quimi Daphne (VP Finance and Controller) Buy 6,812 7.00 47,684
2014-10-03 Quimi Daphne (VP Finance and Controller) Sale 6,812 7.00 47,684
2014-10-03 Peist Kenneth (VP, Legal & IP) Buy 13,853 7.00 96,971
2014-10-03 Peist Kenneth (VP, Legal & IP) Sale 13,853 7.00 96,971
2014-10-02 Yu Julie (VP Clinical Ops & Data Mgmt) Buy 4,759 5.99 28,515
2014-10-02 Yu Julie (VP Clinical Ops & Data Mgmt) Sale 4,759 5.99 28,515
2014-10-02 Castelli Jeff (VP, Program Management) Buy 10,208 6.00 61,299
2014-10-02 Castelli Jeff (VP, Program Management) Sale 10,208 6.00 61,299
2014-09-29 Baird William D Iii (Chief Financial Officer) Buy 25,311 6.09 154,118
2014-09-29 Baird William D Iii (Chief Financial Officer) Sale 25,311 6.09 154,118
2014-09-29 Quimi Daphne (VP Finance and Controller) Buy 10,738 6.10 65,469
2014-09-29 Quimi Daphne (VP Finance and Controller) Sale 10,738 6.10 65,469
2014-09-29 Peist Kenneth (VP, Legal & IP) Buy 28,208 6.09 171,814
2014-09-29 Peist Kenneth (VP, Legal & IP) Sale 28,208 6.09 171,814
2014-08-27 Gershkowitz Jayne (VP, Patient Advocacy) Buy 5,000 7.00 35,000
2014-08-27 Gershkowitz Jayne (VP, Patient Advocacy) Sale 5,000 7.00 35,000
2014-08-27 Sblendorio Glenn (Director) Buy 10,000 6.50 65,000
2014-08-27 Sblendorio Glenn (Director) Sale 10,000 6.50 65,000
2014-08-25 Gershkowitz Jayne (VP, Patient Advocacy) Buy 5,000 6.00 30,000
2014-08-25 Gershkowitz Jayne (VP, Patient Advocacy) Sale 5,000 6.00 30,000
2014-08-25 Dilone Enrique (VP, Technical Operations) Buy 7,000 6.00 42,000
2014-08-25 Dilone Enrique (VP, Technical Operations) Sale 7,000 6.00 42,000
2014-08-25 Valenzano Ken (VP, Pharmacology & Biology) Buy 12,450 6.00 74,700
2014-08-25 Valenzano Ken (VP, Pharmacology & Biology) Sale 12,450 6.00 74,700
2014-08-25 Campbell Bradley L (Chief Operating Officer) Buy 7,000 6.00 42,000
2014-08-25 Campbell Bradley L (Chief Operating Officer) Sale 7,000 6.00 42,000
2014-08-20 Gershkowitz Jayne (VP, Patient Advocacy) Buy 6,080 5.40 32,832
2014-08-20 Gershkowitz Jayne (VP, Patient Advocacy) Sale 6,080 5.40 32,832
2014-08-20 Dilone Enrique (VP, Technical Operations) Buy 12,810 5.40 69,174
2014-08-20 Dilone Enrique (VP, Technical Operations) Sale 12,810 5.40 69,174
2014-08-20 Valenzano Ken (VP, Pharmacology & Biology) Buy 7,000 5.40 37,800
2014-08-20 Valenzano Ken (VP, Pharmacology & Biology) Sale 7,000 5.40 37,800
2014-08-20 Campbell Bradley L (Chief Operating Officer) Buy 18,750 5.40 101,250
2014-08-20 Campbell Bradley L (Chief Operating Officer) Sale 18,750 5.40 101,250
2014-06-30 Perceptive Life Sciences Master Fund Ltd Buy 4,000,000 3.50 14,000,000
2014-06-27 Crowley John F (Chairman & CEO) Option Ex 16,491 .64 10,521
2013-11-20 Glaxosmithkline Plc Buy 1,500,000 2.00 3,000,000
2013-03-15 Barer Sol J (Director) Buy 25,000 3.40 85,000
2012-11-13 Winterbottom Joan (SVP, Human Resources) Buy 1,665 4.54 7,559
2012-07-17 Glaxosmithkline Plc Buy 2,949,581 6.30 18,582,360
2012-03-30 Crowley John F (Chairman & CEO) Option Ex 49,931 .64 31,955
2012-03-07 Sandell Scott D (10% Owner) Buy 925,154 5.70 5,273,377
2012-03-07 Barrett M James (Director) Buy 925,154 5.70 5,273,377
2012-03-07 Perry Mark W (10% Owner) Buy 1,140,000 5.70 6,498,000
2012-03-07 Barris Peter J (10% Owner) Buy 1,140,000 5.70 6,498,000
2012-03-07 Kramlich C Richard (10% Owner) Buy 1,140,000 5.70 6,498,000
2012-03-07 Newhall Charles W Iii (10% Owner) Buy 1,140,000 5.70 6,498,000
2011-08-11 Crowley John F (Chairman & CEO) Buy 10,000 4.20 42,000
2011-06-17 Crowley John F (Executive Chairman) Buy 20,000 6.04 120,800
2011-05-24 Valenzano Ken (VP, Pharmacology & Biology) Sale 2,250 7.50 16,875
2011-05-24 Valenzano Ken (VP, Pharmacology & Biology) Option Ex 2,250 .64 1,435
2010-03-02 Crowley John F (Chairman, President & CEO) Buy 11,898 3.69 43,903
2009-11-04 Barer Sol J (Director) Buy 20,000 4.13 82,600
2009-07-16 Crowley John F (President & CEO) Sale 3,500 10.29 36,001
2009-07-15 Crowley John F (President & CEO) Sale 6,500 10.69 69,472
2009-07-14 Crowley John F (President & CEO) Sale 4,748 10.28 48,818
2009-07-13 Crowley John F (President & CEO) Sale 800 10.09 8,068
 1   2   3 

Insider trading activities including stock purchases, stock sales, and option exercises of FOLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Amicus Therapeutics Inc (symbol FOLD, CIK number 1178879) see the Securities and Exchange Commission (SEC) website.